Hyperfine, Inc. Reports Exit/Disposal Costs

TL;DR

Hyperfine's dumping assets, costs piling up.

AI Summary

Hyperfine, Inc. filed an 8-K on January 29, 2025, reporting costs associated with exit or disposal activities as of January 28, 2025. The company, formerly known as HealthCor Catalio Acquisition Corp. until November 24, 2020, is based in Guilford, Connecticut.

Why It Matters

This filing indicates Hyperfine, Inc. is undergoing restructuring or divesting certain assets, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Reporting exit or disposal costs suggests potential financial distress or strategic shifts that carry inherent business risks.

Key Players & Entities

• Hyperfine, Inc. (company) — Registrant
• HealthCor Catalio Acquisition Corp. (company) — Former company name
• January 28, 2025 (date) — Date of earliest event reported
• January 29, 2025 (date) — Filing date
• November 24, 2020 (date) — Date of name change

FAQ

Key Financial Figures

• $0.0001 — hich registered Class A common stock, $0.0001 par value per share HYPR The Nasdaq
• $0.4 million — currently estimates it will incur up to $0.4 million of costs, consisting primarily of cash

Filing Documents

• hypr-20250128.htm (8-K) — 41KB
• 0000950170-25-010230.txt ( ) — 157KB
• hypr-20250128.xsd (EX-101.SCH) — 25KB
• hypr-20250128_htm.xml (XML) — 5KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On January 28, 2025, Hyperfine, Inc. (the "Company") implemented an organizational restructuring designed to decrease its costs and create a more streamlined organization to support its business priorities. As a result, the Company has terminated approximately 14% of its global workforce. The restructuring affects employees predominantly in technical positions and is largely focused on internally-facing roles as the Company evolves from development stage to commercial stage. Since the initial U.S. Food and Drug Administration ("FDA") clearance of the Swoop system in 2020, the Company has received additional FDA clearances for nine-generations of AI-powered Swoop system software and anticipates obtaining two additional software clearances in 2025. With this streamlined organization, the Company will maintain product development capabilities sufficient to iterate the Swoop system technology further and execute on its strategy. In connection with the restructuring, the Company currently estimates it will incur up to $0.4 million of costs, consisting primarily of cash severance costs, other severance benefits and other related restructuring costs. The Company expects to substantially complete the restructuring in the first quarter of 2025. As a result of this action, the Company expects to further extend its cash runway and now expects that its existing cash and cash equivalents, together with proceeds from the sales of its products and services, will enable it to conduct its planned operations into the second half of 2026. The estimates of costs and expenses that the Company expects to incur in connection with the restructuring and expectations with respect to reduction in net cash required for operating activities are subject to a number of assumptions and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HYPERFINE, INC. Date: January 29, 2025 By: /s/ Brett Hale Brett Hale Chief Administrative Officer, Chief Financial Officer, Treasurer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR